ATLASState Street SPDR S&P Biotech ETF (XBI): outlook, holdings and fees
State Street SPDR S&P Biotech ETF (XBI) is an exchange-traded fund and is managed by State Street Investment Management. The expense ratio is 0.33% and the yield is 0.34%. The ten largest holdings are 17% of the fund.
Fund data as of Oct 14, 2026 · Price Nov 2, 2026
ATLAS view on XBI
| Last price | $152.95 (-1.9%) |
|---|---|
| ATLAS chance of a higher price in 1 month | 51% |
| Likely 1-month range (50%) | $145.32 – $161.58 |
| Normal 1-day range (±1σ) | ±1.8% |
| Distribution yield | 0.34% · quarterly |
ATLAS probabilities use the same calibrated model as every stock page. A fair value is shown for companies, not funds; the holdings below link to the fair value of each company.
XBI fund facts
| Issuer | State Street Investment Management |
|---|---|
| Theme | Biotech |
| Assets under management | $10.3B |
| Expense ratio | 0.33% |
| Number of holdings | 50 |
| Portfolio turnover | 64% |
| Inception | Jan 31, 2006 |
| Exchange | NYSE |
In seeking to track the performance of the S&P Biotechnology Select Industry Index (the index), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index (S&P TMI).
XBI top holdings
| Holding | Sector | Weight |
|---|---|---|
| Moderna Inc MRNA | Healthcare | 2.50% |
| Twist Bioscience Corp TWST | Healthcare | 1.79% |
| Natera Inc NTRA | Healthcare | 1.85% |
| Iovance Biotherapeutics Inc IOVA | Healthcare | 1.60% |
| AbbVie Inc ABBV | Healthcare | 1.60% |
| United Therapeutics Corporation UTHR | Healthcare | 1.58% |
| Biogen Inc BIIB | Healthcare | 1.53% |
| Amgen Inc AMGN | Healthcare | 1.51% |
| Gilead Sciences Inc GILD | Healthcare | 1.47% |
| Halozyme Therapeutics Inc HALO | Healthcare | 1.49% |
Holdings with an ATLAS page link to their probability range, fair value and earnings calendar.
XBI sector breakdown
| Sector | Weight |
|---|---|
| Healthcare | 99.3% |
| Financial Services | 0.7% |
By region: North America 96.6%, Europe Developed 2.1%, United Kingdom 1.3%.
XBI returns and risk
| Year to date | +25.5% |
|---|---|
| 1 year | +46.0% |
| 3 years (annualised) | +29.8% |
| 5 years (annualised) | +4.6% |
| 10 years (annualised) | +9.7% |
| Volatility (3 years) | 25.8% |
| Sharpe ratio (3 years) | 0.96 |
Past returns do not guarantee future results.
XBI: frequently asked questions
What does XBI invest in?
State Street SPDR S&P Biotech ETF invests in a portfolio of securities. Its largest holdings are Moderna Inc (2.5%), Twist Bioscience Corp (1.8%), Natera Inc (1.9%), Iovance Biotherapeutics Inc (1.6%), AbbVie Inc (1.6%).
What is the XBI expense ratio?
0.33% a year: about $33.00 for every $10,000 invested.
What is the XBI dividend yield?
0.34%, paid quarterly. ATLAS does not hold the exact distribution dates for ETFs.
Will XBI go up?
Nobody can know. The ATLAS model puts the chance of a higher price in one month at 51%, with a likely range (50%) of $145.32 to $161.58 from $152.95 today. It is a probability, not a prediction.
How has XBI performed?
Year to date +25.5%, one year +46.0%, three years +29.8% a year, five years +4.6% a year. Past returns do not guarantee future results.
Similar ETFs: Biotech
Educational information, not investment advice. Disclaimer